Fig. 6
In vivo antibacterial efficacy in various infectious mouse models. a ED50 and ED100 of polymers and the imipenem or vancomycin control (a: MDR A. baumannii 10073-caused peritonitis mouse model, intraperitoneal (i.p.) injection at 1 h and 6 h post infection; b: MDR A. baumannii 10073-caused peritonitis mouse model, i.p. injection at 3 h and 8 h post infection; c: MDR E. coli 56809-caused peritonitis mouse model, i.p. injection at 1 h and 6 h post infection; d: MDR K. pneumoniae 8637-caused peritonitis mouse model, i.p. injection at 1 h and 6 h post infection; e: MDR MRSA 25312-induced peritonitis mouse model, i.p. injection at 1 h and 6 h post infection). Colony forming units (CFUs) of A. baumannii 10073 (b) and E. coli 56809 (c) in blood, peritoneal cavity, spleen, liver, and kidney at 24 h post infection. Both polymers were effective against systemic MDR Gram-negative bacterial infections with lower ED50/ED95 values than imipenem (especially A. baumannii 10073- and K. pneumoniae 8637-caused infections), and they also worked against Gram-positive MRSA infection with comparable ED50/ED95 values as compared to vancomycin. The polymers removed bacteria in the blood, peritoneal cavity, and organs more effectively than imipenem especially in the A. baumannii 10073 infection. Means ± s.d., n = 5. One-way ANOVA (Tukey’s post hoc); *p < 0.05; **p < 0.01
